Literature DB >> 21367992

Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.

N D van Burgel1, F Bakels, A C M Kroes, A P van Dam.   

Abstract

CXCL13 in cerebrospinal fluid (CSF) could be an important component for diagnosing Lyme neuroborreliosis (LNB). Levels of intrathecal CXCL13 were determined for 58 LNB patients and 210 controls; sensitivity was 88% and specificity was 89% (cutoff, 250 pg of CXCL13/ml of CSF). Elevated levels of CXCL13 can aid in the diagnosis of LNB, but levels should be interpreted with care.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21367992      PMCID： PMC3122636          DOI： 10.1128/JCM.00084-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Elevation of serum CXCL13 in SLE as well as in sepsis.

Authors:  L Schiffer; J T Kielstein; M Haubitz; H Lührs; T Witte; H Haller; P Kümpers; M Schiffer
Journal:  Lupus       Date:  2010-11-15       Impact factor: 2.911

2.  Sublime diagnosis of Lyme neuroborreliosis.

Authors:  Benjamin M Segal; Eric L Logigian
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

3.  [Cytokine CXCL13--a possible early CSF marker for neuroborreliosis].

Authors:  T A Rupprecht; U Koedel; B Angele; V Fingerle; H-W Pfister
Journal:  Nervenarzt       Date:  2006-04       Impact factor: 1.214

4.  The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis.

Authors:  T A Rupprecht; H W Pfister; B Angele; S Kastenbauer; B Wilske; U Koedel
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

5.  Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis.

Authors:  Ivar Tjernberg; Anna J Henningsson; Ingvar Eliasson; Pia Forsberg; Jan Ernerudh
Journal:  J Infect       Date:  2010-11-16       Impact factor: 6.072

6.  Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection.

Authors:  Daniel P Widney; Elizabeth C Breen; W John Boscardin; Scott G Kitchen; Juan M Alcantar; Jeffrey B Smith; Jerome A Zack; Roger Detels; Otoniel Martínez-Maza
Journal:  J Interferon Cytokine Res       Date:  2005-11       Impact factor: 2.607

7.  The chemokine CXCL13 in acute neuroborreliosis.

Authors:  Makbule Senel; Tobias A Rupprecht; Hayrettin Tumani; Hans W Pfister; Albert C Ludolph; Johannes Brettschneider
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-03       Impact factor: 10.154

8.  B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE).

Authors:  Lena Schiffer; Philipp Kümpers; Ana M Davalos-Misslitz; Marion Haubitz; Hermann Haller; Hans-Joachim Anders; Torsten Witte; Mario Schiffer
Journal:  Nephrol Dial Transplant       Date:  2009-07-13       Impact factor: 5.992

9.  CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.

Authors:  Unn Ljøstad; Ase Mygland
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

10.  Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection.

Authors:  Alberto Cagigi; Frida Mowafi; Linh V Phuong Dang; Klara Tenner-Racz; Ann Atlas; Sven Grutzmeier; Paul Racz; Francesca Chiodi; Anna Nilsson
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113
View more
  33 in total

1.  [CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine].

Authors:  T A Rupprecht; C Lechner; H Tumani; V Fingerle
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 2.  Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Authors:  Juan Carlos Garcia-Monco; Jorge L Benach
Journal:  Ann Neurol       Date:  2019-01       Impact factor: 10.422

3.  [CXCL-13 as a biomarker in the diagnostics of neuroborreliosis].

Authors:  C Waiß; W Kindler; B Ströbele; C Aspöck; S Oberndorfer
Journal:  Nervenarzt       Date:  2017-06       Impact factor: 1.214

Review 4.  [Neuroborreliosis - Diagnostics, treatment and course].

Authors:  R Dersch; S Rauer
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

5.  CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients.

Authors:  Judith N Wagner; S Weis; C Kubasta; J Panholzer; T J von Oertzen
Journal:  J Neurol       Date:  2017-11-13       Impact factor: 4.849

6.  CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation.

Authors:  Jukka Hytönen; Elisa Kortela; Matti Waris; Juha Puustinen; Jemiina Salo; Jarmo Oksi
Journal:  J Neuroinflammation       Date:  2014-06-11       Impact factor: 8.322

7.  Targeting CXCL13 During Neuroinflammation.

Authors:  Amanda K Huber; David N Irani
Journal:  Adv Neuroimmune Biol       Date:  2015-11-13

8.  Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis.

Authors:  Jörg Steinmann; Jürgen Held; Katharina Ziegler; Anca Rath; Christoph Schoerner; Renate Meyer; Thomas Bertsch; Frank Erbguth; Christian Bogdan
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

9.  The predictive value of CXCL13 in suspected Lyme neuroborreliosis: a retrospective cross-sectional study.

Authors:  Fredrikke Christie Knudtzen; Anna Christine Nilsson; Joppe W Hovius; Sigurdur Skarphedinsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-03-14       Impact factor: 3.267

10.  CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma.

Authors:  James L Rubenstein; Valerie S Wong; Cigall Kadoch; Hua-Xin Gao; Ramon Barajas; Lingjing Chen; S Andrew Josephson; Brian Scott; Vanja Douglas; Mekhala Maiti; Lawrence D Kaplan; Patrick A Treseler; Soonmee Cha; Jimmy H Hwang; Paola Cinque; Jason G Cyster; Clifford Lowell
Journal:  Blood       Date:  2013-04-09       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.